- Arvinas, Inc. is a clinical-stage biotechnology company pioneering targeted protein degradation therapeutics, positioning itself as a leader in a transformative area of drug discovery.
- In 2025, Arvinas achieved significant milestones including the submission of its first new drug application and the appointment of Randy Teel, Ph.D., as President and CEO, with a cash runway extending into the second half of 2028.
- The company is advancing multiple clinical candidates, including ARV-102 for Parkinson's disease and ARV-806 for KRAS G12D mutations, with upcoming data presentations set for 2026.
- Ideal buyers include pharmaceutical companies and healthcare providers seeking innovative therapies for serious diseases, as Arvinas addresses critical unmet medical needs with its novel PROTAC platform.
Engineering is the largest team with 158 employees (about 41% of the company). Business Management has 49 employees (~13%), while Healthcare (38) and Operations (36) each account for roughly a tenth of the workforce. Finance and Administration (24), Marketing and Product (21), Information Technology (12), Sales and Support (11), and Human Resources (11) round out core corporate functions. An additional 22 employees are categorized as Other, reflecting specialized or cross-functional roles.
Arvinas maintains a notable concentration in New Haven, CT with 84 employees (about 22%), alongside 51 in New York, NY. Additional site presences include Hartford, CT (11), Boston, MA (10), Philadelphia, PA (9), Branford, CT (7), Guilford, CT (7), San Diego, CA (6), and Wallingford, CT (6). Roughly half of headcount—191 employees—is distributed across other locations, indicating a broad geographic footprint. This mix highlights key regional hubs in the Northeast and a diversified presence across additional U.S. markets.
